Volume 138, Issue 12 pp. 2963-2973
Tumor Immunology and Microenvironment

Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors

Satish Kumar Devarapu

Satish Kumar Devarapu

Translational Immunology, Deutsches Krebsforschungszentrum, Heidelberg, Germany

S.K.D. and S.M. contributed equally to this study

Search for more papers by this author
Srinivas Mamidi

Srinivas Mamidi

Institute of Immunology, University of Heidelberg, Heidelberg, Germany

S.K.D. and S.M. contributed equally to this study

Search for more papers by this author
Frank Plöger

Frank Plöger

Biopharm GmbH, Heidelberg, Germany

Search for more papers by this author
Othmar Dill

Othmar Dill

Target GmbH, Worms, Germany

Search for more papers by this author
Ola Blixt

Ola Blixt

Center for Glycomics, Department of Chemistry, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
Michael Kirschfink

Michael Kirschfink

Institute of Immunology, University of Heidelberg, Heidelberg, Germany

Search for more papers by this author
Reinhard Schwartz-Albiez

Corresponding Author

Reinhard Schwartz-Albiez

Translational Immunology, Deutsches Krebsforschungszentrum, Heidelberg, Germany

Correspondence to: Reinhard Schwartz-Albiez, Translational Immunology, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Tel.: +49-6221-423713, Fax: +49-6221423737, E-mail: [email protected]Search for more papers by this author
First published: 02 February 2016
Citations: 13

Conflict of interest: Nothing to report

Abstract

A small percentage of healthy donors identified in the Western population carry antibodies in their peripheral blood which convey cytotoxic activity against certain human melanoma and neuroblastoma cell lines. We measured the cytotoxic activity of sera and plasmas from healthy donors on the human neuroblastoma cell line Kelly and various melanoma cell lines. Antibodies of IgM isotype, presumably belonging to the class of naturally occurring antibodies, exerted cytotoxic activity in a complement-dependent fashion. Apart from complement-dependent tumor cell lysis, we observed C3 opsonization in all tumor cell lines upon treatment with cytotoxic plasmas. Cell lines tested primarily expressed membrane complement regulatory proteins (mCRP) CD46, CD55 and CD59 to various extents. Blocking of mCRPs by monoclonal antibodies enhanced cell lysis and opsonization, though some melanoma cells remained resistant to complement attack. Epitopes recognized by cytotoxic antibodies were represented by gangliosides such as GD2 and GD3, as evidenced by cellular sialidase pretreatment and enhanced expression of distinct gangliosides. It remains to be clarified why only a small fraction of healthy persons carry these antitumor cytotoxic antibodies.

Abstract

What's new?

A small percentage of healthy blood donors carry IgM antibodies that react with carbohydrate antigens, including tumor-associated gangliosides GD2 and GD3. Ganglioside-targeting IgM can kill via complement activation, however, remains unclear. In this study, donor IgM antibodies effectively killed human neuroblastoma Kelly cells and certain melanoma cells in vitro, using distinct gangliosides as targets for cytotoxic attack. Complement attack was countered, however, by membrane complement regulator proteins (mCRPs), which are highly expressed on most melanoma cells. Despite neutralization with anti-mCRP antibodies, some melanoma cells maintained resistance, suggesting that humoral anti-melanoma activity is prevented through other mechanisms.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.